Vakrakou et al. demonstrated that systemic activation of the NLRP3 inflammasome characterizes SS patients at high risk for lymphoma development and those with established lymphoma, along with significantly increased serum IL-18 and ASC levels. Here, NLRP3 is linked to synovial sarcoma.